### **HUMED LIFESCIENCES**

"Transforming patient access to Dental Implant treatments to those that need it the most"

JULY 2025




# Fundamental Implant Breakthrough in 30+ Years



- Dental implants: Artificial tooth roots replacing missing teeth
- 1980s: Osseointegration breakthrough enabled titanium fusion
- Three decades of only minor surface modifications since then
- HuMed delivers long-awaited structural advancement

## Thriving Market, Billion-Dollar Prizes

\$4.7B Global Dental Implant Market 8.0% CAGR annually and \$7.0B+ expected by 2030



# Proven Success Stories Industry giants with \$2-25B market capitalizations


Company	Revenue	Market Cap	Note
Straumann	~\$1.7B	\$18.5B	Global NO.1
Envista	~\$1.0B	\$3.1B	40% Implant
Ostem	~\$0.6B	\$2.3B	Asia NO.1
Dentsply Sirona	~\$0.5B	\$3.1B	Equipment Focus
Zimmer Biomet	~\$0.3B	\$25B	Orthopedics Focus

<sup>\*</sup> Revenue = Estimated implant segment only | Market Cap = July 2025 data


# World's First Hybrid Dental Implant Technology

### **Revolutionary Bone Ingrowth Technology**

**US Patented Game-Changing Dental Implant** 



# \*PCT for Global Patent Strategy





\*PCT = Patent Cooperation Treaty: International filing system enabling patent protection across 150+ countries simultaneously


"Transforming 30 years of implant limitations into breakthrough patient solutions"


# Redefining Implant Excellence: Safer, Faster, Simpler


Micro-CT (10 μm)
– traditional 2
stage implantation
for 6 weeks postimplantation











40%

\$3K

#### **Improved Contact**

Better bone-to-implant contact compared to traditional implants


### **Cost Savings**

Eliminates bone grafting cost and 6-month waiting period

6 weeks after implantation - New bone labels: alizarin red (earlier) and calcein green (later







\*Publication: Journal of Mechanical Behavior of Biomedical Materials (2020)

3D

### **Stronger Stability**


Enhanced structural stability through 3-dimensional bone ingrowth

100%

### **Compatibility**

Works with existing surgical instruments and procedures

# **Key Milestones on Our Journey**



## Innovation Excellence Powered by Market Mastery



Hongsuk Kim, CEO Global commercialization expert, ex-Samsung/J&J/P&G, Harvard A.M.



Do-Gyoon Kim, CTO, Co-Founder
Ohio State University Professor,
Inventor of Hybrid Implant, 20+ years R&D



Jay Medical Devices & P&G veteran, global scaling expert, MIT MBA

### **Advisory Board**

John Y. Hong

DDS, Serial Entrepreneur, Georgia Tech / Northwestern alum


**Paul Fagan**Serial life science entrepreneur, ECM CEO, MIT MBA

**Dr. Sreenivas Koka**Dean, Univ. of Mississippi Dentistry, ex-Mayo Clinic Chair

Tomas Cole
VP, Dentsply Sirona & Inkbit (3D), MIT MBA

### Strategic Market Expansion: Path to \$10M Revenue

### 4-Year Path to \$10M+ Revenue



### **Go-To-Market Strategy**



#### **Phase 1: Frictionless Adoption**

**Target:** General Practice Dentists (27K)

Same workflow, same cost, revolutionary results

→ Higher margins & patient satisfaction



#### **Phase 2: Gateway Enabler**

Target: Non-implant General Dentists (108K)

Simplified procedures, enhanced outcomes

→ Start implants with confidence



#### **Phase 3: Technical Supremacy & Premium Leadership**

**Target:** Implant Specialists (8K)

Injectable innovation conquering complexity

→ Simplified procedures & clinical excellence

### **Investment Opportunity – Transforming \$4.7B Dental Market**

### **Valuation & Terms**

**Current Valuation** 

\$8M - \$12M

Conservative peer analysis

**Investment Opportunity** 

\$1M - \$2M

8-17% Equity | Q3 2025 Close

### **Strategic Fund Allocation (24 Months)**

### **R&D & Clinical (35%)**

510(k) submission & validation, injectable system optimization

### Regulatory & Launch (25%)

FDA approval, quality systems, manufacturing compliance for entry

### Sales & Marketing (20%)

Digital platform development, KOL network, early customer acquisition

### Manufacturing (15%)

Supply chain establishment & inventory build-up

### **Operations & Team (5%)**

Working capital, key sales/marketing hires & administrative setup

Contact: Hongsuk Kim, CEO | Email: <a href="mailto:hskim@humedlifesciences.com">hskim@humedlifesciences.com</a> | Phone: +82 10 – 4053 - 1257